Publications

Cancer immunology, immunotherapy : CII

Combination of targeted therapy and immunotherapy in melanoma.

01-10-2011

International journal of cancer

Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7.

15-07-2011

Annals of oncology : official journal of the European Society for Medical Oncology

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.

01-05-2011

Clinical and experimental immunology

Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma.

01-12-2010

Current topics in microbiology and immunology

DNA vaccines and intradermal vaccination by DNA tattooing.

26-11-2010

Human gene therapy

Microbead-assisted retroviral transduction for clinical application.

01-10-2010

Cancer immunology, immunotherapy : CII

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.

01-08-2010

Current clinical pharmacology

DNA vaccination in oncology: current status, opportunities and perspectives.

01-08-2010

Annals of oncology : official journal of the European Society for Medical Oncology

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

01-07-2010

International journal of pharmaceutics

Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant?

05-05-2010

Nature medicine

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.

01-05-2010

AAPS PharmSciTech

Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation.

01-03-2010

Journal of controlled release : official journal of the Controlled Release Society

DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.

15-10-2009

World journal of urology

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

01-08-2009

Immunotherapy

Immunotherapeutic strategies: the melanoma example.

01-07-2009

Nature methods

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

01-07-2009

Current opinion in immunology

Preclinical development of T cell receptor gene therapy.

01-04-2009

Journal of pharmaceutical and biomedical analysis

Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.

20-02-2009

Journal of immunology (Baltimore, Md. : 1950)

Requirements for effective antitumor responses of TCR transduced T cells.

01-10-2008

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.

01-10-2008

Anticancer research

Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma.

30-08-2008

Urologia internationalis

Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.

01-07-2008

Journal of immunology (Baltimore, Md. : 1950)

Long-term functionality of TCR-transduced T cells in vivo.

15-05-2008

Journal of immunology (Baltimore, Md. : 1950)

An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease.

01-05-2008

Clinical cancer research : an official journal of the American Association for Cancer Research

Sunitinib for treatment of advanced renal cell cancer: primary tumor response.

15-04-2008

Cancer research

Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.

01-04-2008

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Brain metastases in patients with renal cell cancer receiving new targeted treatment.

01-01-2008

Blood

Selecting highly affine and well-expressed TCRs for gene therapy of melanoma.

15-11-2007

Journal of immunology (Baltimore, Md. : 1950)

In vivo antigen stability affects DNA vaccine immunogenicity.

15-08-2007

Journal of immunotherapy (Hagerstown, Md. : 1997)

Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.

02-05-2007

Laboratory investigation; a journal of technical methods and pathology

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.

01-02-2007

BMC biotechnology

Intravital imaging of fluorescent markers and FRET probes by DNA tattooing.

03-01-2007

Blood

Targeting self-antigens through allogeneic TCR gene transfer.

01-08-2006

Journal of immunology (Baltimore, Md. : 1950)

Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

01-05-2006

Cancer immunology, immunotherapy : CII

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

01-04-2006

Journal of immunological methods

In situ visualization of antigen-specific T cells in cryopreserved human tissues.

20-03-2006

Nature medicine

Design and use of conditional MHC class I ligands.

01-02-2006

Cancer immunology, immunotherapy : CII

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.

01-09-2005

Nature medicine

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression.

01-08-2005

Cancer immunology, immunotherapy : CII

A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor.

01-07-2005

European journal of cancer (Oxford, England : 1990)

Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.

01-02-2005

Clinical cancer research : an official journal of the American Association for Cancer Research

On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients.

15-07-2004

Cancer research

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.

15-03-2004

Journal of immunology (Baltimore, Md. : 1950)

Optimizing the efficacy of epitope-directed DNA vaccination.

15-05-2002

Journal of immunology (Baltimore, Md. : 1950)

A redundant role of the CD3 gamma-immunoreceptor tyrosine-based activation motif in mature T cell function.

15-02-2001

Nature medicine

In situ detection of virus- and tumor-specific T-cell immunity.

01-09-2000

European journal of immunology

Tumor size at the time of adoptive transfer determines whether tumor rejection occurs.

01-05-2000

European journal of immunology

Tracing and characterization of the low-avidity self-specific T cell repertoire.

01-05-2000

The Journal of experimental medicine

Selective expansion of cross-reactive CD8(+) memory T cells by viral variants.

01-11-1999

European journal of immunology

Systemic T cell expansion during localized viral infection.

01-04-1999

Combination of targeted therapy and immunotherapy in melanoma.

Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7.

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.

Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma.

DNA vaccines and intradermal vaccination by DNA tattooing.

Microbead-assisted retroviral transduction for clinical application.

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.

DNA vaccination in oncology: current status, opportunities and perspectives.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant?

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.

Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation.

DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Immunotherapeutic strategies: the melanoma example.

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

Preclinical development of T cell receptor gene therapy.

Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.

Requirements for effective antitumor responses of TCR transduced T cells.

GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.

Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma.

Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.

Long-term functionality of TCR-transduced T cells in vivo.

An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease.

Sunitinib for treatment of advanced renal cell cancer: primary tumor response.

Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.

Brain metastases in patients with renal cell cancer receiving new targeted treatment.

Selecting highly affine and well-expressed TCRs for gene therapy of melanoma.

In vivo antigen stability affects DNA vaccine immunogenicity.

Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.

Intravital imaging of fluorescent markers and FRET probes by DNA tattooing.

Targeting self-antigens through allogeneic TCR gene transfer.

Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

In situ visualization of antigen-specific T cells in cryopreserved human tissues.

Design and use of conditional MHC class I ligands.

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression.

A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor.

Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.

On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients.

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.

Optimizing the efficacy of epitope-directed DNA vaccination.

A redundant role of the CD3 gamma-immunoreceptor tyrosine-based activation motif in mature T cell function.

In situ detection of virus- and tumor-specific T-cell immunity.

Tumor size at the time of adoptive transfer determines whether tumor rejection occurs.

Tracing and characterization of the low-avidity self-specific T cell repertoire.

Selective expansion of cross-reactive CD8(+) memory T cells by viral variants.

Systemic T cell expansion during localized viral infection.

This site uses cookies